CASE REPORT article
Front. Immunol.
Sec. Primary Immunodeficiencies
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1572791
This article is part of the Research TopicCommunity Series in Primary Immunodeficiencies Worldwide: Volume IIIView all articles
Case Report: CD40LG Arg203Ile Variant Underlies Atypical Phenotype of X-Linked Hyper IgM Syndrome
Provisionally accepted- 1Kagoshima University, Kagoshima, Japan
- 2Tokyo Medical and Dental University, Tokyo, Japan
- 3Tokyo University of Pharmacy and Life Sciences, Hachioji, Tōkyō, Japan
- 4Kagoshima University Hospital, Kagoshima, Kagoshima, Japan
- 5Seattle Children's Research Institute, Seattle, Washington, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Hyper IgM syndrome (HIGM) is a rare immunodeficiency caused by impaired immunoglobulin class switching, leading to recurrent infections. The present report describes the case of an 18-year-old man initially diagnosed with common variable immunodeficiency at 3 years of age. Genetic analysis revealed a hemizygous CD40LG missense variant (p.Arg203Ile) associated with X-linked HIGM (XHIGM). Structural and flow cytometric analyses indicated normal CD40 ligand (CD40L) expression on activated CD4 + T-cells but impaired CD40 binding, indicating disrupted immune signaling. Notably, the patient experienced neither bacterial infections requiring hospitalization nor opportunistic infections during 15 years of immunoglobulin replacement therapy. These findings indicate that the p.Arg203Ile variant destabilizes CD40L-CD40 interactions without affecting CD40L expression, suggesting a hypomorphic phenotype. This report highlights the importance of combining genetic testing with functional analysis when evaluating atypical XHIGM presentations to predict clinical severity and provide a scientific basis for personalized treatment strategies. Additional studies are required to assess the long-term outcomes and potential curative therapies for similar cases.
Keywords: Atypical phenotype, CD40 Ligand, Immunoglobulin replacement therapy, structural stability assessment, X-linked hyper IgM syndrome
Received: 07 Feb 2025; Accepted: 27 Mar 2025.
Copyright: © 2025 Nishikawa, Tomomasa, Hijikata, Kasabata, Okamoto, Ochs and Kanegane. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Takuro Nishikawa, Kagoshima University, Kagoshima, Japan
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.